The Genitourinary Cancers Steering Committee (GUSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in genitourinary cancers. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The GUSC's membership comprises NCTN group representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Co-chairs
Jason Efstathiou, M.D., D.Phil.
Massachusetts General Hospital
Boston, MA
Daniel W. Lin M.D.
University of Washington
Seattle, WA
Michael J. Morris, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Members
Rahul R. Aggarwal, M.D.
University of California San Francisco
San Francisco, CA
Leonard J. Appleman, M.D., Ph.D.
University of Pittsburgh Medical Cancer Center Pavilion
Pittsburgh, PA
Leslie Ballas, M.D.
Cedars-Sinai Medical Center
Los Angeles, CA
Alejandro Berlin, M.D., M.Sc.
University of Toronto Princess Margaret Cancer Centre
Toronto, ON, Canada
Toni K. Choueiri, M.D.
Dana-Farber Cancer Institute
Boston, MA
Anthony Crispino
UsTOO Las Vegas
Las Vegas, NV
Elie G. Dib., M.D., M.S. FACP
St. Joseph Mercy Hospital
Ypsilanti, MI
James J. Dignam, Ph.D.
University of Chicago
Chicago, IL
Jared Foster, Ph.D.
National Cancer Institute
Bethesda, MD
Matthew D. Galsky, M.D.
The Tisch Cancer Institute at Mount Sinai
New York, NY
Petros Grivas, M.D., Ph.D., FASCO
University of Washington Fred Hutchinson Cancer Center
Seattle, WA
Naomi B. Haas, M.D.
University of Pennsylvania School of Medicine
Philadelphia, PA
Susan Halabi, Ph.D.
Duke University Medical Center
Durham, NC
Sebastien J. Hotte, M.D., M.Sc., FRCPC
McMaster University
Hamilton, ON, Canada
Wassim Kassouf, M.D., C.M., FRCSC
McGill University
Montréal, QC, Canada
Seth P. Lerner, M.D.
Baylor College of Medicine
Houston, TX
Ravi A. Madan, M.D.
National Cancer Institute
Bethesda, MD
Bhupinder Mann, M.B.B.S.
National Cancer Institute
Bethesda, MD
David T. Marshall, M.D., M.S.
Medical University of South Carolina NCORP
Charleston, SC
Joshua J. Meeks, M.D., Ph.D.
Northwestern Medicine
Chicago, IL
Margaret Mooney, M.D., M.B.A.
National Cancer Institute
Bethesda, MD
Paul L. Nguyen, M.D.
Dana-Farber Cancer Institute
Boston, MA
Daniel P. Petrylak, M.D.
Yale University
New Haven, CT
Susan C. Poteat
Patient Advocate
Dayton, OH
Jonathan R. Rosenberg, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Matthew J. Schipper, Ph.D., M.S.
University of Michigan
Ann Arbor, MI
Daniel E. Spratt, M.D., Ph.D.
University Hospitals of Cleveland, Cleveland Medical Center
Cleveland, OH
Catherine M. Tangen, Dr.PH.
Fred Hutchinson Cancer Research Center
Seattle, WA
NCI CCCT Program Director
Abdul Tawab Amiri, Ph.D.
atawab@mail.nih.gov